Skip to main content

Advertisement

Table 2 Description of the sample

From: Cost-effectiveness analysis of a randomized study of depression treatment options in primary care suggests stepped-care treatment may have economic benefits

All participants
  SC (n = 412)§ TAU (n = 397) ICBT (n = 415) SCP (n = 183) All (n = 1407)
Age (s.d.) 46.9 (17.1) 45.5 (16.3) 46.6 (16.8) 52.3 (17.6) 47.1 (17.0)
Female (%) 75% 78% 70% 61% 73%
PHQ-9 (s.d.), baseline 4.55 (4.95) 4.98 (5.19) 4.2 (4.61) 4.86 (5.54) 4.61 (5.01)
PHQ-9 (s.d.), 12-week 3.85 (2.94) 4.12 (3.09) 3.65 (2.74) 4.04 (3.29) 3.89 (2.98)
within group difference (95% CI)* 0.69 (0.50 to 0.98) 0.88 (0.67 to 1.08) 0.55 (0.37 to 0.73) 0.82 (0.49 to 1.15) 0.72 (0.61 to 0.82)
EQ-5D-5 L (s.d.), baseline 0.86 (0.11) 0.84 (0.14) 0.86 (0.12) 0.86 (0.13) 0.86 (0.12)
EQ-5D-5 L (s.d.), 12-week 0.88 (0.06) 0.87 (0.08) 0.88 (0.07) 0.88 (0.08) 0.88 (0.07)
within group difference (95% CI)** 0.022 (0.017 to 0.026) 0.03 (0.024 to 0.035) 0.022 (0.017 to 0.027) 0.022 (0.014 to 0.03) 0.024 (0.021 to 0.027)
Depressed participants (PHQ-9 > 10 at baseline)
  SC (n = 56) TAU (n = 66) ICBT (n = 50) SCP (n = 34) All (n = 206)
Age (s.d.) 44.7 (16.3) 44.8 (14.2) 42.2 (13.8) 49.0 (16.4) 44.8 (15.1)
Female (%) 80% 70% 70% 74% 74%
PHQ-9 (s.d.), baseline 14.73 (4.17) 14.83 (3.91) 14.28 (3.76) 14.85 (3.84) 14.67 (3.91)
PHQ-9 (s.d.), 12-week 9.9 (2.48) 9.94 (2.31) 9.64 (2.24) 9.98 (2.28) 9.86 (2.32)
within group difference (95% CI)* 4.83 (4.37 to 5.28) 4.85 (4.46 to 5.24) 4.64 (4.21 to 5.08) 4.88 (4.33 to 5.42) 4.8 (4.58 to 5.02)
EQ-5D-5 L (s.d.), baseline 0.68 (0.18) 0.63 (0.2) 0.67 (0.22) 0.68 (0.21) 0.66 (0.2)
EQ-5D-5 L (s.d.), 12-week 0.78 (0.1) 0.74 (0.12) 0.77 (0.13) 0.78 (0.12) 0.76 (0.12)
within group difference (95% CI)** 0.095 (0.075 to 0.115) 0.118 (0.096 to 0.139) 0.1 (0.075 to 0.126) 0.094 (0.064 to 0.125) 0.103 (0.092 to 0.115)
  1. §: This table represents numbers of patients at baseline. Patient numbers at 12-week are available in the Additional file 1
  2. *: There was significant improvement between baseline and 12-week post-randomization (p = 0.015 for SC, 0.004 for TAU, 0.037 for ICBT, and 0.086 for SCP in all participants and < 0.001 in depressed participants). There was no statistically significant difference between groups at baseline and 12 weeks (p > 0.1 in all participants including depressed participants)
  3. **: There was significant improvement in EQ-5D-5 L scores between baseline and 12-week post-randomization (p < 0.001 for SC, < 0.001 for TAU, 0.002 for ICBT, and 0.066 for SCP in all participants and p < 0.002 for SC, < 0.001 for TAU, < 0.007 for ICBT, and 0.033 for SCP in depressed participants). All pairwise differences of the means among the intervention arms were not statistically significant (p > 0.5)